Anixa Biosciences (NASDAQ:ANIX) CEO Acquires $52,500.00 in Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar acquired 21,000 shares of Anixa Biosciences stock in a transaction dated Friday, June 12th. The shares were bought at an average cost of $2.50 per share, with a total value of $52,500.00. Following the completion of the purchase, the chief executive officer owned 630,812 shares in the company, valued at approximately $1,577,030. This represents a 3.44% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Anixa Biosciences Stock Up 8.2%

Shares of NASDAQ ANIX opened at $2.91 on Friday. The stock’s fifty day simple moving average is $2.78 and its 200 day simple moving average is $3.04. The stock has a market capitalization of $99.00 million, a price-to-earnings ratio of -9.39 and a beta of 0.59. Anixa Biosciences Inc has a 52-week low of $2.32 and a 52-week high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last announced its earnings results on Wednesday, June 10th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.03. As a group, analysts anticipate that Anixa Biosciences Inc will post -0.31 earnings per share for the current year.

Institutional Trading of Anixa Biosciences

Hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE grew its position in Anixa Biosciences by 1.7% during the third quarter. Bank of America Corp DE now owns 213,955 shares of the company’s stock valued at $706,000 after purchasing an additional 3,645 shares in the last quarter. GSA Capital Partners LLP boosted its stake in shares of Anixa Biosciences by 4.9% during the 3rd quarter. GSA Capital Partners LLP now owns 81,897 shares of the company’s stock valued at $270,000 after buying an additional 3,790 shares during the period. Prosperity Wealth Management Inc. boosted its stake in shares of Anixa Biosciences by 14.5% during the 3rd quarter. Prosperity Wealth Management Inc. now owns 41,800 shares of the company’s stock valued at $138,000 after buying an additional 5,300 shares during the period. Geode Capital Management LLC boosted its stake in shares of Anixa Biosciences by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 350,915 shares of the company’s stock valued at $1,095,000 after buying an additional 7,271 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in shares of Anixa Biosciences by 13.6% during the 1st quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock valued at $158,000 after acquiring an additional 7,300 shares in the last quarter. 29.13% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on ANIX. HC Wainwright reiterated a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Anixa Biosciences in a report on Wednesday. Citigroup restated a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. Wall Street Zen cut shares of Anixa Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Finally, D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research note on Wednesday, April 8th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $8.50.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.